Open an account

Nektar Therapeutics

NKTR · NASDAQ

$39.22+$2.58 (+7.04%)TodayMarket closed ·
Prev close $36.64

About NKTR

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. The company is headquartered in San Francisco, California and currently employs 63 full-time employees. The company is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. The company is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.

Employees
63
Headquarters
San Francisco, California
Listed
May 3, 1994
Sector
Health Care
Industry
Pharmaceuticals
Website
nektar.com

NKTR key statistics

Market cap
1.25B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.92M
Volume
1.06M
Open price
$36.99
High today
$39.25
Low today
$36.50
52 Week high
$109.00
52 Week low
$33.40

Nektar Therapeutics (NKTR) at a glance

Nektar Therapeutics (NKTR) last traded at $39.22, with a market cap of 1.25B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $36.50 and $39.25. The current price is 7.5% above the day's low and 0.1% below its high.

Volume so far is 1.06M shares, below the average of 1.92M shares a day.

Over the past year Nektar Therapeutics has ranged from $33.40 to $109.00, and now sits 8% of the way up that range.

Nektar Therapeutics met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$1.23 per share against an estimate of -$2.02.

The average analyst price target is $152.89, 289.8% above the current price, from 13 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

69%of 13 analyst ratings say Buy
  • Buy69.2%
  • Hold30.8%
  • Sell0.0%
Price target · 12 analystsAvg $152.89
Low
$50.50
Now
$39.22
High
$201.60

NKTR earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 21.4% on average.

  1. Q3 FY24: reported -$2.70 per share against an estimate of -$3.23
  2. Q4 FY24: reported -$2.40 per share against an estimate of -$2.57
  3. Q1 FY25: reported -$3.60 per share against an estimate of -$2.51
  4. Q2 FY25: reported -$2.95 per share against an estimate of -$3.10
  5. Q3 FY25: reported -$1.87 per share against an estimate of -$2.74
  6. Q4 FY25: reported -$1.78 per share against an estimate of -$2.52
  7. Q1 FY26: reported -$1.82 per share against an estimate of -$1.63
  8. Q2 FY26: reported -$1.23 per share against an estimate of -$2.02

NKTR news

  • Press releasePRNewswire

    New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026

  • Press releasePRNewswire

    /UPDATE -- Nektar Therapeutics/

  • Press releasePRNewswire

    New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis

  • Press releasePRNewswire

    Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026

  • Press releasePRNewswire

    Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Vandana Singh

    Eli Lilly Did Breach Implied Covenant of Good Faith With Nektar Therapeutics, Jury Funds

  • Press releasePRNewswire

    Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Press releasePRNewswire

    Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis

Similar companies

Companies in the same industry as Nektar Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.